Borisso
1999–2001
M01) AT NATIONAL LEVEL IN DDD/1000/DAY:
STEROID ANTIINFLAMMATORY DRUGS (GROUP
ANALYSIS OF CONSUMPTION OF NON-
Patients starting a treatment with COXIBs
nificantly more severe and costly than patients who
GPAs are likely to have a previous history of GIDs sig-
in particular when evaluating co-prescription rates with
GPAs in patients treated with antiinflammatories.

OBJECTIVES: To focus on the Bulgarian market of M01
group for the period 1999–2001; the most consumptive
active principles (APs) within M01; to determine the
trend in M01 consumption and within. METHODS:
M01 consumption at national level has been calculated
by ATC/DDD methodology and expressed in
DDD/1000/day. Data have been collected from: a) the
import of wholesalers, b) the local industry sale reports
for the domestic market. Comparison has been made with
M01 consumption in Norway and Sweden (expressed
in DDD/1000/day). RESULTS: M01 consum-
tion at national level has been calculated as follows: 1999—
14,216; 2000—13,764; and 2001—15,565. The most
consumptive APs within M01 were: Diclofenac (D) 1999—
8,448; 2000—8,728; and 2001—9,753; Piroxicam (P) 1999—
3,380; 2000—2,892; and 2001—2,761; Indometacin (Ind) 1999—
1,457; 2000—1,061; and 2001—1,104; Ketoprofen (K) 1999—
0,192; 2000—0,439; and 2001—0,699; Tenoxicam (T) 1999—
0,598; 2000—0,172; and 2001—0,699. Ibuprofen (Ib) con-
sumption was: 1999—0,439; 2000—0,303; and 2001—
0. The coxib Rofecoxib (R) consumption was registered
initially in 2001—0,054. CONCLUSIONS: M01 con-
sumption 1999–2001 did not show significant variations.
The national demand for M01 is approximately 14
DDD/1000/day. M01 consumption in Norway and Sweden
was higher. D as the most consumptive AP at a
national level was about 67% of M01 consumption due
to 4 locally produced products. Dynamics within the
group was: D and K increased slightly; Ind showed rela-
tively steady-state position; P slightly decreased; the trend
in T consumption could not be defined distinctly; Ib
decreased in consumption; Coxibs were with limited
place within M01. In comparison with Bulgaria, M01
consumption model in Norway and Sweden showed some
differences.